IPO registrations (S-1, F-1) · Registrants
IMMUNIC, INC.
- SEC CIK
- 1280776 · filings on EDGAR ↗
- Name on the registration
- VITAL THERAPIES INC
- Former names
- VITAL THERAPIES INC (2004–2019)
- Registration
- Form S-1, first filed 2013-10-11, last 2014-09-30; 2 initial registrations, 8 amendments
- Outcome
- Final prospectus filed 2014-04-17; declared effective 2014-04-16
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 1200 AVENUE OF THE AMERICAS, SUITE 200, New York, X1 10036
- EIN
- 56-2358443
- Ticker
- IMUX (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- IMMUNIC, INC. on the corporate pages
Offering terms
- Proposed price range
- $13.00–$15.00 per share (S-1/A filed 2014-04-09)
- Final price
- $12.00 per share, below the range (424B4 filed 2014-04-17, an initial public offering)
- Shares sold
- 4,500,000
- Gross proceeds
- $54,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol VTL
- Lead underwriters
- Credit Suisse (1,350,000 shares); Merrill Lynch (1,800,000 shares)
- Syndicate
- BofA Securities; William Blair (787,500); Canaccord Genuity (562,500)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: IMMUNIC, INC. EXACT (EIN (EXACT))
- Form D issuer: IMMUNIC, INC. EXACT (CIK (EXACT))
- SEC filer: IMMUNIC, INC. EXACT (CIK (EXACT))
Filings 15
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2013-10-11 | S-1 | S-1 (registration) | VITAL THERAPIES INC | 0001193125-13-398007 ↗ |
| 2013-10-30 | S-1/A | S-1/A (amendment) | VITAL THERAPIES INC | 0001193125-13-418800 ↗ |
| 2013-11-06 | S-1/A | S-1/A (amendment) | VITAL THERAPIES INC | 0001193125-13-428786 ↗ |
| 2013-11-15 | S-1/A | S-1/A (amendment) | VITAL THERAPIES INC | 0001193125-13-443012 ↗ |
| 2014-03-11 | S-1/A | S-1/A (amendment) | VITAL THERAPIES INC | 0001193125-14-092594 ↗ |
| 2014-04-03 | S-1/A | S-1/A (amendment) | VITAL THERAPIES INC | 0001193125-14-129462 ↗ |
| 2014-04-07 | S-1/A | S-1/A (amendment) | VITAL THERAPIES INC | 0001193125-14-132509 ↗ |
| 2014-04-09 | S-1/A | S-1/A (amendment) | VITAL THERAPIES INC | 0001193125-14-136892 ↗ |
| 2014-04-16 | EFFECT | EFFECT (declared effective) | VITAL THERAPIES INC | 9999999995-14-001010 ↗ |
| 2014-04-17 | 424B4 | 424B4 (final prospectus) | VITAL THERAPIES INC | 0001193125-14-147570 ↗ |
| 2014-09-22 | S-1 | S-1 (registration) | VITAL THERAPIES INC | 0001193125-14-347286 ↗ |
| 2014-09-30 | S-1/A | S-1/A (amendment) | VITAL THERAPIES INC | 0001193125-14-358928 ↗ |
| 2014-10-02 | EFFECT | EFFECT (declared effective) | VITAL THERAPIES INC | 9999999995-14-002985 ↗ |
| 2014-10-03 | 424B4 | 424B4 (final prospectus) | VITAL THERAPIES INC | 0001193125-14-363321 ↗ |
| 2015-05-26 | EFFECT | EFFECT (declared effective) | VITAL THERAPIES INC | 9999999995-15-001451 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2014-04-09 | S-1/A | registration statement | $13.00–$15.00 | $6.53 | 4,500,000 | $29,385,000 | Nasdaq VTL | 5 | primary document; range, price line, shares headline, proceeds computed, underwriting table 1, cover names 4 | document ↗ |
| 2014-04-17 | 424B4 | final prospectus | $12.00 | 4,500,000 | $54,000,000 | Nasdaq VTL | 5 | primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Ashley Robert A. | Officer | Chief Scientific Officer, EVP; Chief Technical Officer, EVP; See Remarks | 6 | 2014–2019 | |
| BIENAIME JEAN JACQUES | Director | 12 | 2014–2018 | ||
| CROXFORD PHILIP M | Director | 5 | 2014–2017 | ||
| Godshall Douglas Evan | Director | 8 | 2014–2018 | ||
| Halperin Errol R. | Director | 8 | 2014–2018 | ||
| Henry Andrew | Officer | See Remarks; VP, Clinical Operations | 5 | 2014–2018 | |
| Loewen Andrea | Officer | See Remarks | 2 | 2014–2016 | |
| Millis J. Michael | Director | 6 | 2014–2018 | ||
| MURAWSKI RICHARD M | Officer | Vice President, Manufacturing | 4 | 2014–2018 | |
| Nash Duane | Director; Director,Officer; Officer | Executive Chairman; President; See Remarks | 29 | 2014–2025 | |
| Satter Muneer A | Director,TenPercentOwner | 18 | 2014–2018 | ||
| SEARS LOWELL | Director | 7 | 2014–2018 | ||
| STEER RANDOLPH C | Director | 5 | 2014–2017 | ||
| Stern Aron | Officer | Chief Administrative Officer; See Remarks | 5 | 2014–2018 | |
| Swanson Michael V. | Officer | Chief Financial Officer, EVP; See Remarks | 5 | 2014–2019 | |
| Winters Terence E. | Director,Officer | Co-Chairman and CEO; See Remarks | 11 | 2014–2017 | |
| DUNN JOHN MICHAEL | Officer | General Counsel; General Counsel and Secretary | 8 | 2014–2019 | |
| Cohen Cheryl | Director | 7 | 2015–2018 | ||
| Hasnain Faheem | Director | 8 | 2016–2018 | ||
| Cox Russell J. | Director,Officer | Chief Executive Officer | 3 | 2018–2019 | |
| Global Life Bioventure V Sarl | TenPercentOwner | 1 | 2019 | ||
| Groeppel Manfred | Officer | Chief Operating Officer | 5 | 2019–2021 | |
| Lim Richard J. | TenPercentOwner | 1 | 2019 | ||
| LSP V Cooperatieve U.A. | TenPercentOwner | 1 | 2019 | ||
| LSP V Management B.V. | TenPercentOwner | 1 | 2019 | ||
| Neermann Joerg | Director | 14 | 2019–2026 | ||
| Nessi Claudio | TenPercentOwner | 1 | 2019 | ||
| Omega Fund V GP, L.P. | TenPercentOwner | 1 | 2019 | ||
| Omega Fund V GP Manager, Ltd. | TenPercentOwner | 1 | 2019 | ||
| Omega Fund V, L.P. | TenPercentOwner | 1 | 2019 | ||
| Ossipow Vincent | Director | 4 | 2019–2022 | ||
| Paster Anne-Mari | TenPercentOwner | 1 | 2019 | ||
| Stampacchia Otello | TenPercentOwner | 1 | 2019 | ||
| van den Bossche Jan | Director | 5 | 2019–2022 | ||
| Vitt Daniel | Director; Director,Officer | CEO and Director; CEO, President; Chief Executive Officer; President and CEO | 19 | 2019–2026 | |
| Fund N.V. | TenPercentOwner | 1 | 2019 | ||
| Patel Sanjay S | Officer | Chief Financial Officer | 2 | 2019 | |
| HOWSON TAMAR D | Director | 10 | 2019–2026 | ||
| PHILLIPS BARCLAY A | Director | 11 | 2019–2026 | ||
| Whaley Glenn | Officer | Chief Financial Officer; PAO and Controller; PAO and PFO; PFO and PAO | 24 | 2020–2026 | |
| Muehler Andreas | Officer | Chief Medical Officer | 12 | 2021–2025 | |
| Toernsen Monika Maria | Director | 6 | 2022–2025 | ||
| Rudick Richard Alan | Director | 9 | 2023–2026 | ||
| Tardio Jason | Officer | President and COO | 7 | 2024–2026 | |
| Skerjanec Simona | Director | 5 | 2024–2026 | ||
| BIOTECHNOLOGY VALUE FUND II LP | Director,Other | 2 | 2026 | ||
| BIOTECHNOLOGY VALUE FUND L P | Director,Other | 2 | 2026 | ||
| Biotechnology Value Trading Fund OS LP | Director,Other | 2 | 2026 | ||
| BVF GP HOLDINGS LLC | Director,Other | 2 | 2026 | ||
| BVF I GP LLC | Director,Other | 2 | 2026 | ||
| BVF II GP LLC | Director,Other | 2 | 2026 | ||
| BVF INC/IL | Director,Other | 2 | 2026 | ||
| BVF PARTNERS L P/IL | Director,Other | 2 | 2026 | ||
| BVF Partners OS Ltd. | Director,Other | 2 | 2026 | ||
| LAMPERT MARK N | Director,Other | 2 | 2026 | ||
| Nagel Robert Thorvald | Director | 2 | 2026 | ||
| Congleton Jon | Director | 3 | 2026 | ||
| Panzara Michael A. | Officer | Chief Medical Officer | 2 | 2026 | |
| BONNEY MICHAEL W | Director | 2 | 2026 | ||
| Lundgren Erik | Officer | Chief Executive Officer | 2 | 2026 | |
| Ridloff Elena | Director | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2026-03-04 | IMMUNIC, INC. | Biotechnology | $200,000,000 | $200,000,000 | 43 | 1 |
| 2024-01-19 | IMMUNIC, INC. | Biotechnology | $240,000,000 | $80,000,016 | 19 | 1 |
| 2022-10-18 | IMMUNIC, INC. | Biotechnology | $60,000,002 | $60,000,002 | 14 | 1 |
| 2014-02-04 | VITAL THERAPIES INC | Biotechnology | $13,928,129 | $13,928,129 | 37 | 2 |
| 2014-01-31 | VITAL THERAPIES INC | Biotechnology | $31,979,470 | $31,979,470 | 62 | 1 |
| 2012-02-17 | VITAL THERAPIES INC | Biotechnology | $1,500,000 | $929,831 | 7 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | IMMUNIC, INC. | Form D private offerings | CIK (EXACT) | |
| SEC filer | IMMUNIC, INC. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | IMMUNIC, INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.